CWC
DRNA

Carolinas Wealth Consulting’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Carolinas Wealth Consulting’s Portfolio DRNA Stock Details DRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-47
Closed -$1K – 1067
2020
Q3 		$1K Buy
+47
New +$973 ﹤0.01% 914

Other funds holding DRNA

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Carolinas Wealth Consulting's DRNA Position: Q4 2020 in Review

Carolinas Wealth Consulting sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q4 2020, closing a stake of 47 shares — an estimated $1K sold.

Carolinas Wealth Consulting first reported a position in DRNA in Q3 2020 and held it in 1 quarter. The position peaked at $1K in Q3 2020. 173 funds tracked by Wall St. Rank hold DRNA as of Q4 2020.

  • Carolinas Wealth Consulting reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q4 2020 after selling out during the quarter.
  • Carolinas Wealth Consulting sold 47 Dicerna Pharmaceuticals, Inc. shares in Q4 2020, an estimated $1K.
  • Carolinas Wealth Consulting first reported a position in Dicerna Pharmaceuticals, Inc. in Q3 2020 and held it in 1 quarter.
  • Carolinas Wealth Consulting's Dicerna Pharmaceuticals, Inc. position peaked at $1K in Q3 2020.
  • 173 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q4 2020.

Based on Carolinas Wealth Consulting's 13F filing for Q4 2020, filed 16 Feb 2021.